Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma

Hari, Parameswaran; Raj, Renju V.; Olteanu, Horatiu

doi:10.1056/nejmc1605684

Cited by 86 publications

(64 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although clinical response to treatment in our patient was short, the mechanism of targeting systemic‐ and CNS‐disease of CD 38‐positive ENKL cells with an anti‐CD38‐antibody, as described by Hari et al, is documented here for the second time in the literature. Our case suggests that daratumumab passes the blood‐brain barrier and targets malignant cells in the CSF.…”

supporting

confidence: 55%

“…Recently, PD1 blockage was shown as a possibly potent strategy after L‐asparaginase regimens . Furthermore, a recently published case report was able to document a remission in a CD38‐positive, extensively pretreated ENKL relapse after treatment with daratumumab …”

mentioning

confidence: 98%

“…Flow cytometric characterization of the bone marrow aspirate confirmed CD38‐positivity of the malignant population. Due to lack of treatment options, a therapeutic attempt with daratumumab was started, based on a published case report by Hari et al Treatment was initiated with a weekly administration of daratumumab (16 mg/kg bodyweight, a total of 2200 mg i.v.) 10 days after systemic progression was confirmed.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Systemic treatment of a patient with relapsed and refractory extranodal NK/T‐cell lymphoma (ENKL) and meningeosis leukemica with daratumumab

Aeppli

Graf

Hitz

2018

Hematological Oncology

View full text Add to dashboard Cite

show abstract

supporting

confidence: 55%

mentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Systemic treatment of a patient with relapsed and refractory extranodal NK/T‐cell lymphoma (ENKL) and meningeosis leukemica with daratumumab

Aeppli

Graf

Hitz

2018

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Investigators also found that all-trans retinoid acid (ATRA) given before daratumumab could enhance CD38 expression on T cells, leading to improved results (79). A report of the use of daratumumab for post-allotransplant ENKT (80) has demonstrated a complete remission with associated normalization of EBV titers. A phase II international study of daratumumab for relapsed/refractory ENKL is ongoing in Asia (NCT02927925).…”

Section: Immunotherapeutic Strategies For T Cell Leukemia and Lymphomamentioning

confidence: 99%

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Ghione

Moskowitz

Paola

et al. 2018

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of review: novel immunotherapies such as checkpoint inhibitors, bispecific and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells. These are rare diseases with generally poor clinical outcomes. This review describes the rational and preliminary results of these approaches for people with T cell lymphoma and leukemia. Recent findings: for T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. Summary: In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.

show abstract

“…Daratumumab is a monoclonal anti‐CD38 antibody approved by the European Medicines Agency for treatment of adult patients with refractory multiple myeloma or those who are ineligible for autologous stem cell transplantation . Apart from multiple myeloma, daratumumab is also being investigated as treatment for relapsed and/or refractory extranodal NK/T‐cell lymphoma, nasal type . Zaja et al showed that 17% of ALK‐negative ALCL in adults ( n = 48) express CD38, though none of the 25 ALK‐positive ALCL was positive .…”

mentioning

confidence: 99%